New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:10 EDTIDNX, GILDIdentix intends to appeal Norway court decision regarding patent invalidity case
Idenix Pharmaceuticals (IDIX) announced that it intends to file an appeal to challenge the Oslo, Norway District Court's decision in a patent invalidity case concerning Idenix's co-owned Norwegian patent NO 330 755 that covers certain 2'-methyl-2'-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus, or HCV, and other flaviviridae infections. In September 2012, Gilead Sciences Europe, a subsidiary of Gilead Sciences, (GILD), filed a lawsuit in the Court claiming that Idenix's Norwegian patent NO 330 755 is invalid. Idenix subsequently filed a counter claim that a patent owned by Gilead covering similar subject matter is invalid and unenforceable. On March 21, the Court determined that Idenix's patent is invalid and that Gilead's patent is valid. aria Stahl, senior vice president and general counsel at Idenix said, "We intend to challenge this decision in proceedings in the Appeal Court in Oslo, as we maintain that our patent is valid and enforceable under Norwegian law. Idenix has invested significant resources in nucleoside drug discovery and in building an intellectual property portfolio that supports the discovery and development of drugs to treat HCV. We remain confident in the belief that Gilead infringes U.S. and European patents co-owned by Idenix that cover methods of treating the hepatitis C virus using either 2'-methyl nucleosides or 2'-methyl-2'-fluoro nucleoside and will continue to aggressively defend our intellectual property portfolio."
News For IDNX;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
11:58 EDTGILDStocks with call strike movement; GILD YHOO
Gilead (GILD) November 130 call option implied volatility increased 2% to 28, Yahoo (YHOO) October 46 call option implied volatility decreased 2% to 29 according to IVolatility.
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open: AAPL FB GILD BABA BAC MU WYNN MSFT NFLX
07:32 EDTGILDJuno pact leaves Celgene set for growth past Revlimid, says Deutsche Bank
Subscribe for More Information
June 29, 2015
16:30 EDTGILDFDA sued by advocacy groups for Gilead Hep-C drug trial data, Reuters says
Subscribe for More Information
June 25, 2015
09:34 EDTGILDActive equity options trading on open
Active equity options trading on open: AAPL FB NFLX AMZN BAC CVX TWTR INTC GILD BBBY
June 23, 2015
14:10 EDTGILDGilead price target raised to $150 from $130 at Argus
Subscribe for More Information
June 22, 2015
09:40 EDTGILDActive equity options trading on open
Subscribe for More Information
June 19, 2015
16:00 EDTGILDOptions Update; June 19, 2015
iPath S&P 500 VIX Short-Term Futures up 11c to 18.21, Option volume leaders: AAPL TWTR BAC T FB GILD NFLX BABA AAL MU AMZN
06:40 EDTGILDPatent linked to Gilead's Solvadi rejected by China, Reuters reports
Subscribe for More Information
June 18, 2015
07:36 EDTGILDReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use